Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript
…
8,850€
-4,84%
Echtzeit-Aktienkurs Theravance Biopharma
Bid:
Ask:
Nachrichten zur Theravance Biopharma Aktie
Theravance Biopharma, Inc. (TBPH) Q2 2024 Earnings Call Transcript
…
Theravance Biopharma, Inc. (TBPH) Q1 2024 Earnings Call Transcript
…
Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript
…
Theravance Biopharma, Inc. 2023 Q4 - Results - Earnings Call Presentation
…
Theravance Biopharma shares down on lung disease trial failure
Theravance Biopharma shares fell more than 20% after the company reported that its therapeutic for chronic obstructive pulmonary disease (COPD), a…
Theravance Biopharma’s stock slides 21% after Phase 4 trial of COPD treatment fails to meet main goal
…
Theravance Biopharma, Inc. (TBPH) Q3 2023 Earnings Call Transcript
…
Insiderhandel: SVP, COMM & MEDICAL AFFAIRS verkauft Aktien von Theravance Biopharma im Wert von 17.112$
Farnum, Rhonda - Vorstand - Tag der Transaktion: 2023-08-22...…
Insiderhandel: SVP, RESEARCH & DEVELOPMENT verkauft Aktien von Theravance Biopharma im Wert von 23.197$
Graham, Richard A. - Vorstand - Tag der Transaktion: 2023-08-11...…
Form 10-Q Theravance Biopharma, For: Jun 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of 18.75% and 9.80%, respectively, for the quarter ended June 2023. Do…
Form 8-K Theravance Biopharma, For: Aug 07
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
Q2 2023 YUPELRI® (revefenacin) net sales of $55.0 million, recognized by Viatris, up 12% from Q2 20221 Q2 2023 YUPELRI…
Theravance Biopharma Earnings Preview
read more...…
Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023
DUBLIN, July 24, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2023 financial results and…
Insiderhandel: SVP, RESEARCH & DEVELOPMENT verkauft Aktien von Theravance Biopharma im Wert von 22.848$
Graham, Richard A. - Vorstand - Tag der Transaktion: 2023-07-14...…
Insiderhandel: SVP, RESEARCH & DEVELOPMENT verkauft Aktien von Theravance Biopharma im Wert von 24.822$
Graham, Richard A. - Vorstand - Tag der Transaktion: 2023-06-14...…
Insiderhandel: SVP, COMM & MEDICAL AFFAIRS verkauft Aktien von Theravance Biopharma im Wert von 19.923$
Farnum, Rhonda - Vorstand - Tag der Transaktion: 2023-06-08...…
Form 8-K Theravance Biopharma, For: Jun 09
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Why Is Theravance Bio (TBPH) Down 3.8% Since Last Earnings Report?
Theravance Bio (TBPH) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…
Insiderhandel: SVP, RESEARCH & DEVELOPMENT verkauft Aktien von Theravance Biopharma im Wert von 26.146$
Graham, Richard A. - Vorstand - Tag der Transaktion: 2023-05-15...…
Form 10-Q Theravance Biopharma, For: Mar 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of 11.11% and 24.64%, respectively, for the quarter ended March 2023. Do…
Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
Q1 2023 YUPELRI® (revefenacin) net sales of $47.0 million, recognized by Viatris, up 8% from Q1 20221 Q1 2023 YUPELRI…
Earnings Preview: Theravance Biopharma (TBPH) Q1 Earnings Expected to Decline
Theravance Bio (TBPH) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…
Theravance Biopharma to Report First Quarter 2023 Financial Results on May 8, 2023
DUBLIN, April 24, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2023 financial results and…
Insiderhandel: SVP, RESEARCH & DEVELOPMENT verkauft Aktien von Theravance Biopharma im Wert von 27.597$
Graham, Richard A. - Vorstand - Tag der Transaktion: 2023-04-14...…
Form 8-K Theravance Biopharma, For: Apr 17
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Theravance Biopharma ticks higher amid appointment of new director
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Theravance Biopharma to Participate in an Upcoming Investor Conference
DUBLIN, April 10, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the 22nd Annual Needham Virtual Healthcare…
Theravance Bio (TBPH) Down 2% Since Last Earnings Report: Can It Rebound?
Theravance Bio (TBPH) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…
Insiderhandel: SVP, RESEARCH & DEVELOPMENT verkauft Aktien von Theravance Biopharma im Wert von 23.973$
Graham, Richard A. - Vorstand - Tag der Transaktion: 2023-03-14...…
Insiderhandel: SVP, COMM & MEDICAL AFFAIRS verkauft Aktien von Theravance Biopharma im Wert von 40.800$
Farnum, Rhonda - Vorstand - Tag der Transaktion: 2023-03-09...…
Form 10-K Theravance Biopharma, For: Dec 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Theravance Biopharma Finally Shelves Failed JAK Inhibitor Program, Lays Off Staff
read more...…
Form 8-K Theravance Biopharma, For: Feb 28
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of -5% and 19.73%, respectively, for the quarter ended December 2022. Do…
Earnings Preview: Theravance Biopharma
read more...…
Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets
Strategic priorities focused on continued Net Sales growth for YUPELRI® (revefenacin) and conduct of the ampreloxetine Phase 3 study (CYPRESS)…
Form 8-K Theravance Biopharma, For: Jan 09
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…